Feb 6 (Reuters) - Eli Lilly and Co LLY.N:
PALATIN COMPLETES PHASE 2 OBESITY STUDY WITH MC4R BREMELANOTIDE PLUS GLP-1/GIP TIRZEPATIDE
PALATIN TECHNOLOGIES INC - TOPLINE DATA RESULTS EXPECTED LATER THIS QUARTER
Source text: ID:nPnbyzcCga
Further company coverage: LLY.N